Key result
The withdrawal of the HeartWare device has introduced a single-device era dominated by HeartMate 3, necessitating new surgical techniques and device adaptations for advanced heart failure patients.
Why the study?
The abrupt withdrawal of the HeartWare device from the market introduced a one-device era dominated by the HeartMate 3, prompting clinical, economic, and surgical challenges.
Answers are grounded in this paper and cite their sources.
The abrupt withdrawal of the HeartWare device has created a 'one-device era' dominated by HeartMate 3, presenting new clinical and surgical challenges, particularly for pediatric patients and those requiring device exchange.
Heart failure (HF) is linked to to high mortality rates and recurrent hospitalisations despite medical and device-based achievements. The use of left ventricular assist devices (LVADs) has improved survival among patients with advanced HF. Significant progress has been achieved with the new generation of continuous-flow devices, particularly with the fully magnetically levitated HeartMate 3. In June 2021, Medtronic announced the abrupt withdrawal of the HeartWare device from the market. This decision has introduced a new era in which the field of mechanical support for advanced HF patients is dominated by a single device – the HeartMate 3. The direct clinical and economic consequences of this change will necessitate new surgical considerations. Because of the expected need for HeartWare device replacement in small patients, new surgical techniques and device adaptation will be needed. The new single-device era will hopefully encourage scientists and engineers to create innovations in the advanced HF arena. Special considerations should be taken during the COVID-19 pandemic when treating patients with LVADs.
No takes yet. Share an insight, caveat, or question.
Moady et al. (2022) conducted a review in Advanced heart failure. Left ventricular assist devices (HeartMate 3) was evaluated. The withdrawal of the HeartWare device has introduced a single-device era dominated by HeartMate 3, necessitating new surgical techniques and device adaptations for advanced heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: